Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical company specializing in cell therapy platforms, has announced the expansion of its technological initiatives to include artificial intelligence and blockchain solutions. Following the successful launch of its Technology Division, the company aims to enhance operational efficiency and customer engagement through these advanced technologies.
CEO Dave Mehalick expressed enthusiasm about building upon the momentum generated by their Technology Division, particularly in AI, while exploring blockchain opportunities. The company views this expansion as a strategic move to remain at the forefront of technological developments and adapt to the evolving digital marketplace.
Coeptis Therapeutics Holdings (Nasdaq: COEP), un'azienda biofarmaceutica specializzata in piattaforme di terapia cellulare, ha annunciato l'espansione delle sue iniziative tecnologiche per includere soluzioni di intelligenza artificiale e blockchain. Dopo il lancio riuscito della sua Divisione Tecnologia, l'azienda mira a migliorare l'efficienza operativa e il coinvolgimento dei clienti attraverso queste tecnologie avanzate.
Il CEO Dave Mehalick ha espresso entusiasmo nel voler costruire sul slancio generato dalla loro Divisione Tecnologia, in particolare nell'IA, mentre esplora opportunità nel blockchain. L'azienda considera questa espansione un passo strategico per rimanere all'avanguardia nello sviluppo tecnologico e adattarsi al mercato digitale in evoluzione.
Coeptis Therapeutics Holdings (Nasdaq: COEP), una empresa biofarmacéutica especializada en plataformas de terapia celular, ha anunciado la expansión de sus iniciativas tecnológicas para incluir soluciones de inteligencia artificial y blockchain. Tras el exitoso lanzamiento de su División de Tecnología, la empresa busca mejorar la eficiencia operativa y la participación del cliente a través de estas tecnologías avanzadas.
El CEO Dave Mehalick expresó su entusiasmo por aprovechar el impulso generado por su División de Tecnología, particularmente en IA, mientras explora oportunidades en blockchain. La empresa ve esta expansión como un movimiento estratégico para mantenerse a la vanguardia de los desarrollos tecnológicos y adaptarse al mercado digital en evolución.
Coeptis Therapeutics Holdings (Nasdaq: COEP)는 세포 치료 플랫폼을 전문으로 하는 생명공학 회사로, 인공지능 및 블록체인 솔루션을 포함하도록 기술 이니셔티브를 확장한다고 발표했습니다. 기술 부서의 성공적인 출범 이후, 회사는 이러한 고급 기술을 통해 운영 효율성과 고객 참여를 향상시키는 것을 목표로 하고 있습니다.
CEO 데이브 메할릭은 AI 분야에서의 기술 부서의 성과를 기반으로 한 기회와 블록체인 기회를 탐색하는 것에 대해 열정을 가지고 있다고 밝혔습니다. 회사는 이 확장을 기술 발전의 최전선에 서고 진화하는 디지털 시장에 적응하기 위한 전략적 조치로 보고 있습니다.
Coeptis Therapeutics Holdings (Nasdaq: COEP), une entreprise biopharmaceutique spécialisée dans les plateformes de thérapie cellulaire, a annoncé l'élargissement de ses initiatives technologiques pour inclure des solutions d'intelligence artificielle et de blockchain. Suite au lancement réussi de sa Division Technologie, l'entreprise vise à améliorer l'efficacité opérationnelle et l'engagement des clients grâce à ces technologies avancées.
Le PDG Dave Mehalick a exprimé son enthousiasme à bâtir sur l'élan généré par leur Division Technologie, en particulier dans le domaine de l'IA, tout en explorant des opportunités de blockchain. L'entreprise considère cette expansion comme un mouvement stratégique pour rester à la pointe des développements technologiques et s'adapter au marché numérique en évolution.
Coeptis Therapeutics Holdings (Nasdaq: COEP), ein biopharmazeutisches Unternehmen, das sich auf Zelltherapie-Plattformen spezialisiert hat, hat die Erweiterung seiner technologischen Initiativen bekannt gegeben, um lösungen für künstliche Intelligenz und Blockchain einzubeziehen. Nach dem erfolgreichen Start seiner Technologiedivision möchte das Unternehmen die Betriebseffizienz und das Kundenengagement durch diese fortschrittlichen Technologien verbessern.
CEO Dave Mehalick äußerte seine Begeisterung dafür, den Schwung, der durch ihre Technologiedivision erzeugt wurde, insbesondere im Bereich KI, aufzugreifen und gleichzeitig Blockchain-Möglichkeiten zu erkunden. Das Unternehmen betrachtet diese Expansion als strategischen Schritt, um an der Spitze technologischer Entwicklungen zu bleiben und sich an den sich wandelnden digitalen Markt anzupassen.
- Successfully launched Technology Division with AI capabilities
- Strategic expansion into blockchain technology
- None.
Coeptis Harnesses AI Advances and Blockchain Initiatives to Drive Operational Efficiency and Strategic Growth
Following the successful launch of its Technology Division and the introduction of transformative AI capabilities, Coeptis has demonstrated significant promise in enhancing operational efficiency and customer engagement. The Company recognizes the enormous potential for AI to revolutionize the pharmaceutical landscape while exploring the opportunities provided by blockchain technology.
Dave Mehalick, President and CEO of Coeptis, stated, "We are thrilled to build upon the momentum we've generated with our Technology Division, particularly in the area of artificial intelligence, as we look to advance our initiatives leveraging blockchain technology. This expansion signifies not only our commitment to remaining at the forefront of technological developments but also our dedication to exploring new avenues that align with the rapidly evolving digital marketplace."
"The integration of blockchain initiatives into the Technology Division's portfolio reflects Coeptis's mission to adapt to emerging trends and leverage new market opportunities for enhanced value creation," added Mr. Mehalick. As we embark on this new journey, we are confident in our ability to drive innovation and explore synergies that will benefit our customers and shareholders.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of
Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-leverages-artificial-intelligence-and-blockchain-for-next-generation-innovation-302358118.html
SOURCE Coeptis Pharmaceuticals, Inc.
FAQ
What new technologies is Coeptis Therapeutics (COEP) implementing in 2025?
How is Coeptis Therapeutics (COEP) leveraging AI in its operations?
What is the purpose of Coeptis Therapeutics' (COEP) blockchain initiative?
When did Coeptis Therapeutics (COEP) announce its AI and blockchain expansion?
